MedinCell
MedinCell is a French clinical- and commercial-stage biopharmaceutical company that licenses its proprietary BEPO long-acting injectable polymer platform to pharmaceutical partners, generating royalties from Teva's UZEDY (risperidone LAI) and co-developing pipeline assets in schizophrenia, pain, contraception, and malaria.
- Company typePublic
- Founded2003
- HeadquartersJacou, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What MedinCell does
MedinCell SA is a clinical- and commercial-stage biopharmaceutical company headquartered near Montpellier, France, that develops long-acting injectable (LAI) drug formulations on its proprietary BEPO technology platform. BEPO uses PEG-PLA diblock and triblock copolymers that form a small, fully bioresorbable subcutaneous or local depot upon contact with aqueous environments; the depot releases the entrapped active pharmaceutical ingredient by diffusion and polymer degradation at therapeutic levels for days, weeks, or months from a single injection, with release kinetics tunable via the hydrophilicity and ratio of the diblock and triblock components. The platform underpins 15 active programs spanning neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The lead commercial product, UZEDY (risperidone LAI, marketed under the SteadyTeq trademark by Teva), received FDA approval in April 2023 for schizophrenia and was expanded in October 2025 to include Bipolar I Disorder, with additional approvals in Canada and South Korea in 2025.
MedinCell operates a licensing- and royalty-driven business model rather than direct commercialization. Its primary commercial partner is Teva Pharmaceuticals, which markets UZEDY in the United States, Canada, and South Korea and is co-developing olanzapine LAI (TEV-749/mdc-TJK), for which both FDA NDA acceptance (February 2026) and EMA MAA acceptance (May 2026) have been secured. The company also has a strategic co-development agreement with AbbVie for next-generation LAIs, a partnership with Arthritis Innovation Corporation for mdc-CWM (intra-articular celecoxib for post-operative pain), and non-dilutive grant funding from the Bill & Melinda Gates Foundation and Unitaid for global health programs targeting malaria (mdc-STM) and contraception (mdc-WWM). FY2026 total income was €24.3 million, with UZEDY royalties contributing €9.3 million (+42% year-over-year, now 38% of total revenue) and the company reporting a net loss of €31.29 million against a year-end cash position of €80.8 million, bolstered by a €48 million private placement completed in March 2026.
The company employs approximately 140 people across more than 25 nationalities, with 73% of staff dedicated to R&D and 91% participating as shareholders. MedinCell is publicly listed on Euronext Paris under the ticker MEDCL, was included in the MSCI World Small Cap Index effective November 24, 2025, and holds ISS ESG Prime Status with a Corporate Rating upgraded from C+ to B in 2025. The board and management team include veterans of Teva, Novartis, Alcon, AbbVie Ventures, and Intra Cellular Therapies, supporting the company's stated "Shift to Growth" strategy of transitioning toward a royalty-driven commercial model.
MedinCell firmographics
Firmographics- Name
- MedinCell
- Legal name
- MedinCell SA
- Website
- https://medincell.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- MedinCell is a French clinical- and commercial-stage biopharmaceutical company that licenses its proprietary BEPO long-acting injectable polymer platform to pharmaceutical partners, generating royalties from Teva's UZEDY (risperidone LAI) and co-developing pipeline assets in schizophrenia, pain, contraception, and malaria.
- Ownership category
- akta.pro rank
MedinCell industry classification
Industry- Product category
- Long-acting injectable pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where MedinCell is headquartered
LocationHeadquarters
- HQ city
- Jacou
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
MedinCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Royalty Income from UZEDY: MedinCell receives mid- to high-single-digit royalties on UZEDY net sales from Teva. UZEDY royalties reached EUR 9.3 million in FY2026, representing 38% of total revenue, up from 22% in FY2025. Teva's net sales of UZEDY reached $215 million in FY2026, up 52.5% year over year.
- Commercial Milestone Payments: MedinCell is eligible for up to $105 million in commercial milestone payments upon achievement of annual sales thresholds for UZEDY. Additional $4 million payment upon approval for Olanzapine LAI.
- R&D Grants and Non-dilutive Funding: Funding from foundations for global health programs: $19 million grant from Bill & Melinda Gates Foundation for mdc-WWM contraceptive program, up to $6.4 million from Unitaid for malaria program (mdc-STM), with extension grants of up to $6 million. $3 million grant from Gates Foundation for ivermectin-based malaria treatment (mdc-STM).
- Co-development and Licensing Agreements: Strategic co-development and licensing partnerships including AbbVie collaboration for next-generation LAI therapies. Revenue from upfront payments, development milestones, and royalties from partnered programs.
- Private Placement and Equity Financing: EUR 48 million private placement completed March 2026 through issuance of 2,370,000 new shares at EUR 20.35 per share. EUR 40 million loan agreement with European Investment Bank signed November 2022.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Royalty-based revenue model from licensed products |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
MedinCell product offering
Product offeringCore offering
MedinCell develops and licenses its proprietary BEPO® long-acting injectable technology platform, which uses PEG-PLA diblock and triblock copolymers to form a small, fully bioresorbable depot under the skin that delivers active pharmaceutical ingredients at therapeutic levels for days, weeks, or months following a single subcutaneous or local injection. The commercial-stage product UZEDY® (risperidone long-acting injectable) is FDA-approved for schizophrenia and Bipolar I Disorder and is marketed by partner Teva. The company monetizes the technology through royalties, milestone payments, and co-development partnerships with leading pharmaceutical companies and global health foundations.
Product overview
MedinCell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments. The portfolio centers on the proprietary BEPO® technology platform, which enables controlled drug delivery via bioresorbable depots. The commercial-stage product UZEDY® (risperidone LAI) is marketed by Teva for schizophrenia and Bipolar I Disorder. The pipeline includes mdc-TJK (olanzapine LAI, Phase 3 complete, NDA/MAA accepted), mdc-CWM (post-operative pain, Phase 3 complete), mdc-WWM (contraceptive, Phase 1), mdc-STM (malaria, preclinical), and mdc-AbbVie-1 (confidential, partnership with AbbVie). Programs span neuroscience, immunology, oncology, endocrinology, infectious diseases, and pain management. The company has 15 active programs total.
Differentiator
Problem solved
Functional benefit
Brands
- UZEDY: Monthly and every 2 months subcutaneous risperidone for treatment of schizophrenia and Bipolar I Disorder; FDA-approved long-acting injectable based on BEPO technology, marketed by Teva in the US
- BEPO
- SteadyTeq
Products and services
- UZEDY® (risperidone long-acting injectable) Monthly and every-two-months subcutaneous risperidone long-acting injectable based on BEPO® technology for the treatment of schizophrenia and Bipolar I Disorder in adults. FDA-approved in April 2023 for schizophrenia, with expanded indication for Bipolar I Disorder approved October 2025. Marketed by Teva in the US under the SteadyTeq® license and also approved in Canada (marketed as LONGAVO®) and South Korea in 2025.
- mdc-TJK (Olanzapine long-acting injectable) Investigational once-monthly subcutaneous long-acting injection of olanzapine for treatment of schizophrenia, in partnership with Teva Pharmaceuticals. Phase 3 complete with SOLARIS trial data showing no PDSS (Postinjection Delirium/Sedation Syndrome) and no required post-injection monitoring, differentiating from existing olanzapine LAIs that carry FDA black box warnings and REMS requirements. NDA accepted by FDA in February 2026 and Marketing Authorization Application accepted by EMA in May 2026.
- mdc-CWM (intra-articular celecoxib) One-time intra-articular celecoxib sustained-release formulation for post-operative pain relief after total knee replacement surgery, active for up to three months post-surgery. Collaboration with Arthritis Innovation Corporation (AIC) based in Toronto, Canada, which finances and conducts clinical development. Phase 3 results positive, with the goal of reducing opioid dependency.
- mdc-WWM (6-month subcutaneous contraceptive) Six-month active injectable bioresorbable subcutaneous contraceptive using a non-MPA progestin molecule. Could be the first contraceptive combining 6-month duration, subcutaneous injection, full bio-resorption, and affordability for women in low- and middle-income countries. Funded by up to $19 million grant from the Bill & Melinda Gates Foundation as part of MedinCell's Global Access strategy. Preclinical and Phase 1 activities ongoing.
- mdc-STM (3-month ivermectin for malaria) Three-month ivermectin long-acting injectable for malaria transmission control. Administered at the beginning of transmission season to eliminate malaria-transmitting mosquitoes. Collaboration with IRD, IRSS, and CIRDES research institutes. Supported by Unitaid (up to $6.4M initial grant plus up to $6M extension) and the Bill & Melinda Gates Foundation ($3M grant). Licensed non-exclusively to the Medicines Patent Pool for distribution via the public sector in low- and middle-income countries.
- mdc-AbbVie-1 (next-generation long-acting injectable) Confidential next-generation long-acting injectable therapy program developed under strategic co-development and licensing agreement with AbbVie, signed April 2024. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas; specific indication and molecule details are confidential. Clinical trials are expected to begin in 2027.
- BEPO® Technology Platform (licensed as SteadyTeq®) Proprietary long-acting injectable technology platform enabling controlled drug delivery at therapeutic levels for several days, weeks, or months following subcutaneous or local injection of a small, fully bioresorbable depot. Composed of PEG-PLA diblock and triblock copolymers that form an in-situ depot millimeters under the skin when exposed to aqueous environment. Licensed to Teva under the SteadyTeq® trademark and used in UZEDY® and TEV-749 olanzapine LAI products. The platform enables tunable release kinetics by adjusting copolymer hydrophilicity and relative ratio.
Quantifiable outcome
- UZEDY net sales grew 63% from $117M in 2024 to $191M in 2025
- +5 more outcomes
Companies that use MedinCell
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
MedinCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MedinCell partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and secondary.
- AbbViecoreStrategic co-development and licensing agreement to develop next-generation long-acting injectable therapies. First clinical development program with AbbVie has been delayed, with trials now expected to begin in 2027. The collaboration represents MedinCell's expansion beyond neuroscience into other therapeutic areas.
- Teva PharmaceuticalscoreTeva is the primary commercial partner for MedinCell's BEPO technology. Teva markets UZEDY (risperidone LAI) in the US, Canada, and South Korea following FDA approval in April 2023 and subsequent approvals. Teva is also co-developing olanzapine LAI (TEV-749/mdc-TJK) with MedinCell's SteadyTeq technology. Teva reported $191 million in UZEDY net sales in 2025 and $215 million in FY2026. MedinCell receives mid- to high-single-digit royalties on net sales.
- Medicines Patent PoolsecondaryLicense agreement for malaria transmission-fighting product distribution via public sector in low- and middle-income countries. Part of MedinCell's Global Access strategy to ensure equitable access to health products.
- Unitaidcore$6.4 million initial grant and up to $6 million extension grant for mdc-STM, a 3-month ivermectin formulation to combat malaria transmission. MedinCell signs license agreement with Medicines Patent Pool for distribution via public sector in LMICs.
- Arthritis Innovation Corporation (AIC)secondaryCollaboration for mdc-CWM, a one-time intra-articular celecoxib formulation for post-operative pain relief after total knee replacement. AIC finances and conducts clinical development activities. Phase 3 results have been positive.
- Bill & Melinda Gates FoundationcoreUp to $19 million grant for development of mdc-WWM, a 6-month injectable bioresorbable subcutaneous contraceptive. The Global Access strategy aims to ensure widespread availability with affordable pricing in emerging economies. Foundation holds non-exclusive license for non-commercial market in low- and middle-income countries.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
MedinCell competitors and assessment
Company assessmentOthers
- Teva Pharmaceutical Industries: Teva is MedinCell's primary commercialization partner for UZEDY and olanzapine LAI. Teva provides commercial reach and infrastructure; they are not a peer in the technology sense but their commercial performance directly drives MedinCell's royalty stream.
- PolyPeptide Group: PolyPeptide is a CDMO specializing in peptide-based and sustained-release injectable formulations. Not a direct competitor but adjacent infrastructure provider in the LAI/depot formulation ecosystem that MedinCell operates within.
Direct peers
- Camurus: Camurus is a Swedish specialty pharma with FluidCrystal technology for long-acting injectable and depot formulations. Markets Buvidal (buprenorphine LAI) for opioid use disorder. Closely comparable as a technology-platform LAI developer partnering with larger pharma.
- Otsuka Pharmaceutical: Otsuka markets Abilify Maintena and Abilify Asimtufii (aripiprazole LAI) for schizophrenia. Direct competitor to UZEDY/risperidone LAI in the long-acting injectable antipsychotic space and comparable therapeutic-area presence.
- Alkermes: Alkermes is a leading long-acting injectable technology company developing Vivitrol (naltrexone), Aristada (aripiprazole LAI), and Lybalvi. Directly comparable to MedinCell as a specialty pharma using proprietary depot technology to enable sustained-release injectables for CNS and addiction.
- Intra-Cellular Therapies: Developed Caplyta (lumateperone) for schizophrenia and bipolar, with a focus on CNS specialty pharma. Acquired by J&J in April 2025 for $14.6B. Comparable business model as a CNS-focused specialty pharma with innovative oral therapeutics for the same patient population.
- Indivior: Indivior is a specialty pharma focused on addiction treatment with Sublocade (buprenorphine LAI). Comparable as a single-indication LAI specialist that built a commercial-stage franchise around sustained-release depot technology.
Regional players
- Luye Pharma Group: Luye Pharma developed a risperidone long-acting injectable (Rykindo) approved in the US and operates a microsphere-based LAI platform. Comparable as a global LAI developer; primary geographic focus on China and Asia.
Emerging players
- Heron Therapeutics: Heron Therapeutics developed sustained-release postoperative pain management products using its Biochronomer polymer technology. Comparable as a specialty pharma using polymer-based LAI/depot technology for pain and CNS indications.
Broad incumbents
- Johnson & Johnson (Janssen): Janssen markets Risperdal Consta (pioneer risperidone LAI) and Invega Sustenna/Hafyera (paliperidone LAI), the dominant long-acting injectable antipsychotics. Broad incumbent in MedinCell's primary commercial category with established market leadership.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
MedinCell social profiles
Digital presenceMedinCell compliance and trust
Trust signalCompliance1 record
MedinCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
MedinCell leadership team
Management profileNumber of profiles
Profiles19 records
MedinCell funding detail
Funding detailFunding overview
Funding rounds12 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MedinCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MedinCell
What does MedinCell do?
MedinCell develops and licenses its proprietary BEPO® long-acting injectable technology platform, which uses PEG-PLA diblock and triblock copolymers to form a small, fully bioresorbable depot under the skin that delivers active pharmaceutical ingredients at therapeutic levels for days, weeks, or months following a single subcutaneous or local injection. The commercial-stage product UZEDY® (risperidone long-acting injectable) is FDA-approved for schizophrenia and Bipolar I Disorder and is marketed by partner Teva. The company monetizes the technology through royalties, milestone payments, and co-development partnerships with leading pharmaceutical companies and global health foundations.
Is MedinCell a public or private company?
MedinCell is a public company. It is classified as public and is currently operating.
When was MedinCell founded?
MedinCell was founded in 2003. It employs 101 to 250 people.
Where is MedinCell based?
MedinCell is headquartered in Jacou, France, in the Europe region.
How does MedinCell make money?
Five revenue lines are on record. Royalty Income from UZEDY is the primary driver. The others are commercial Milestone Payments, R&D Grants and Non-dilutive Funding, co-development and Licensing Agreements and private Placement and Equity Financing.
Who are MedinCell's main competitors?
Others on record are Teva Pharmaceutical Industries and PolyPeptide Group. Direct peers are Camurus, Otsuka Pharmaceutical, Alkermes, Intra-Cellular Therapies and Indivior. Luye Pharma Group is listed as a regional player. Heron Therapeutics is listed as an emerging player. Johnson & Johnson (Janssen) is listed as a broad incumbent.
Does MedinCell have an API?
No public API is recorded for MedinCell.
What industry is MedinCell in?
MedinCell's product category is Long-acting injectable pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.